SIBN - SI-BONE Inc Stock Price, Fair Value and News

14.74USD-0.39 (-2.58%)Delayed as of 17 May 2024, 12:06 pm ET

Market Summary

USD14.74-0.39

Delayedas of 17 May 2024, 12:06 pm

-2.58%

SIBN Alerts

Losses in recent quarter

SIBN Stock Price

View Fullscreen

SIBN RSI Chart

SIBN Valuation

Market Cap

623.4M

Price/Earnings (Trailing)

-14.46

Price/Sales (Trailing)

4.33

Price/Free Cashflow

-27.3

SIBN Price/Sales (Trailing)

SIBN Profitability

Return on Equity

-26.05%

Return on Assets

-19.27%

Free Cashflow Yield

-3.66%

SIBN Fundamentals

SIBN Revenue

Revenue (TTM)

144.0M

Rev. Growth (Yr)

15.77%

Rev. Growth (Qtr)

-2.55%

SIBN Earnings

Earnings (TTM)

-43.1M

Earnings Growth (Yr)

1.99%

Earnings Growth (Qtr)

0.72%

Breaking Down SIBN Revenue

52 Week Range

14.7229.51

(Low)(High)

Last 7 days

-2.6%

Last 30 days

-1.4%

Last 90 days

-27.7%

Trailing 12 Months

-40.0%

How does SIBN drawdown profile look like?

SIBN Financial Health

Current Ratio

9.76

Debt/Equity

0.22

Debt/Cashflow

-0.43

SIBN Investor Care

Shares Dilution (1Y)

17.11%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	144.0M	0	0	0
2023	116.7M	124.4M	132.0M	138.9M
2022	92.1M	95.5M	99.7M	106.4M
2021	77.0M	85.2M	87.1M	90.2M
2020	69.1M	66.9M	71.1M	73.4M
2019	57.7M	60.3M	63.1M	67.3M
2018	49.8M	51.7M	53.5M	55.4M
2017	0	0	0	48.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SI-BONE Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	dunn jeffrey w	sold	-4,985	14.5351	-343	-
Apr 03, 2024	recupero anthony j	sold	-14,379	15.6298	-920	president, commercial ops
Apr 02, 2024	recupero anthony j	sold	-51,272	15.5041	-3,307	president, commercial ops
Apr 02, 2024	maheshwari anshul	sold	-37,473	15.4531	-2,425	chief financial officer
Mar 13, 2024	nishimura mika	sold	-40,550	16.22	-2,500	-
Mar 13, 2024	recupero anthony j	sold	-56,022	16.8237	-3,330	president, commercial ops
Feb 16, 2024	dunn jeffrey w	sold	-87,172	20.955	-4,160	-
Feb 16, 2024	francis laura	sold	-808,591	20.955	-38,587	chief executive officer
Feb 16, 2024	recupero anthony j	sold	-163,910	20.955	-7,822	president, commercial ops
Feb 16, 2024	maheshwari anshul	sold	-153,726	20.955	-7,336	chief financial officer

Which funds bought or sold SIBN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Voya Investment Management LLC	reduced	-11.53	-96,405	214,562	-%
May 15, 2024	AE Wealth Management LLC	sold off	-100	-457,311	-	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.02	-55,989	197,097	-%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-70.58	-3,253,170	968,482	-%
May 15, 2024	Caption Management, LLC	new	-	965,830	965,830	0.01%
May 15, 2024	Bellevue Group AG	added	810	16,033,100	18,661,100	0.28%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	reduced	-40.43	-3,113	2,702	-%
May 15, 2024	Man Group plc	new	-	213,841	213,841	-%
May 15, 2024	Kent Lake Capital LLC	added	5.33	-1,499,240	6,896,760	3.01%
May 15, 2024	Soleus Capital Management, L.P.	sold off	-100	-7,174,760	-	-%

Are Funds Buying or Selling SIBN?

Are funds buying SIBN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SIBN

No. of Funds

SIBN Alerts

Losses in recent quarter

Unveiling SI-BONE Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	first light asset management, llc	6.25%	2,532,227	SC 13G
Feb 14, 2024	orbimed advisors llc	5.3%	2,144,631	SC 13G/A
Feb 13, 2024	champlain investment partners, llc	2.96%	1,197,537	SC 13G/A
Feb 13, 2024	vanguard group inc	5.97%	2,419,831	SC 13G
Feb 09, 2024	brown advisory inc	10.3%	4,155,434	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	3,907,197	SC 13G/A
Jan 22, 2024	integrated core strategies (us) llc	3.0%	1,203,538	SC 13G/A
May 11, 2023	integrated core strategies (us) llc	5.4%	2,081,497	SC 13G
Feb 14, 2023	first light asset management, llc	6.10%	2,104,337	SC 13G
Feb 14, 2023	orbimed advisors llc	9.3%	3,201,100	SC 13G/A

Recent SEC filings of SI-BONE Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 18, 2024	PRE 14A	PRE 14A
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to SI-BONE Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.4B	40.3B	-3.99%	-3.65%	32.43	4.52	-2.84%	-3.08%
BDX	68.4B	19.7B	2.45%	-5.81%	51.31	3.47	4.82%	-17.56%
ALGN	20.6B	3.9B	-10.40%	-6.17%	44.52	5.25	5.72%	46.72%
BAX	17.9B	14.9B	-11.17%	-17.84%	6.76	1.2	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.25	2.76	6.16%	35.06%
HSIC	9.5B	12.5B	4.37%	-2.87%	24.53	0.76	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.13	3.23	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-63	1.5	0.23%	91.03%
AXNX	3.5B	387.1M	0.46%	29.28%	-216.68	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.97	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.88	0.4	7.94%	-1661.78%
ANIK	378.1M	169.3M	-	-1.96%	-4.92	2.23	7.49%	-244.90%
ANGO	257.2M	324.0M	-1.38%	-32.77%	-1.34	0.79	-3.19%	-337.41%
APYX	53.0M	50.5M	10.79%	-74.07%	-2.32	1.05	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.22%	29.03%	-0.09	0.28	5.77%	8.23%

SI-BONE Inc News

Latest updates

SI-BONE Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-2.6%	37,867,000	38,859,000	34,014,000	33,305,000	32,708,000	31,953,000	26,432,000	25,585,000	22,439,000	25,230,000	22,286,000	22,194,000	20,442,000	22,144,000	20,373,000	14,049,000	16,821,000	19,811,000	16,182,000	16,317,000	14,991,000
Gross Profit	4.1%	29,865,000	28,676,000	26,973,000	26,987,000	26,784,000	26,864,000	22,264,000	22,120,000	19,456,000	21,855,000	19,808,000	19,819,000	18,242,000	19,869,000	17,795,000	11,932,000	14,889,000	17,765,000	14,552,000	14,729,000	13,465,000
Operating Expenses	1.8%	41,908,000	41,182,000	38,142,000	38,950,000	38,077,000	38,158,000	35,830,000	40,001,000	36,324,000	35,786,000	33,007,000	32,784,000	29,817,000	27,740,000	26,470,000	22,071,000	26,771,000	26,250,000	25,133,000	22,867,000	22,264,000
S&GA Expenses	1.6%	29,387,000	28,937,000	26,512,000	27,492,000	27,313,000	27,609,000	25,669,000	28,843,000	25,605,000	26,353,000	23,525,000	23,084,000	20,922,000	19,982,000	18,772,000	15,755,000	19,281,000	19,266,000	16,443,000	16,727,000	15,815,000
R&D Expenses	4.4%	4,345,000	4,162,000	3,919,000	3,656,000	3,291,000	3,480,000	3,089,000	3,478,000	3,580,000	3,049,000	3,288,000	3,149,000	2,955,000	2,426,000	2,778,000	2,165,000	2,090,000	1,776,000	1,874,000	1,946,000	1,683,000
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-0.41	-0.45	-0.47	-0.50	-0.44	-0.47	-0.47	-0.49	-0.19	-0.19	-0.20
Interest Expenses	-1.0%	881,000	889,500	884,000	850,000	838,000	881,000	755,000	622,000	561,000	568,000	2,658,000	1,075,000	1,064,000	1,085,000	1,102,000	2,683,000	1,231,000	1,243,000	1,243,000	1,233,000	1,230,000
EBT Margin	-	-	-	-	-	-	-	-	-	-	-	-0.50	-0.51	-0.57	-0.60	-0.54	-0.57	-0.56	-0.57	-0.28	-0.29	-0.30
Net Income	0.7%	-10,904,000	-10,983,000	-10,022,000	-11,206,000	-11,125,000	-11,175,000	-14,158,000	-18,513,000	-17,410,000	-14,477,000	-15,872,000	-13,981,000	-12,242,000	-8,979,000	-9,474,000	-12,472,000	-12,772,000	-9,098,000	-11,306,000	-8,654,000	-9,345,000
Net Income Margin	4.1%	-0.30	-0.31	-0.33	-0.38	-0.47	-0.58	-0.65	-0.69	-0.67	-0.63	-0.59	-0.52	-	-	-	-	-	-	-	-	-
Free Cashflow	-184.7%	-9,653,000	-3,390,000	-3,486,000	-6,304,000	-13,332,000	-8,435,000	-10,099,000	-16,842,000	-15,786,000	-14,489,000	-9,732,000	-10,366,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.9%	224	230	231	234	149	158	158	166	177	191	194	207	216	223	154	159	168	117	121	127	132
Current Assets	-3.7%	204	211	211	213	128	138	139	148	161	176	186	199	208	218	150	155	162	111	113	119	129
Cash Equivalents	-3.7%	32.00	33.00	53.00	111	23.00	21.00	26.00	24.00	27.00	63.00	60.00	48.00	37.00	54.00	56.00	66.00	68.00	10.00	13.00	11.00	13.00
Inventory	4.0%	21.00	20.00	22.00	21.00	18.00	17.00	17.00	16.00	15.00	11.00	10.00	8.00	7.00	6.00	5.00	5.00	6.00	5.00	5.00	4.00	4.00
Net PPE	8.4%	17.00	16.00	16.00	18.00	17.00	16.00	14.00	13.00	10.00	9.00	8.00	8.00	7.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00
Liabilities	-4.7%	58.00	61.00	57.00	56.00	55.00	59.00	55.00	55.00	54.00	56.00	50.00	53.00	54.00	54.00	52.00	51.00	52.00	54.00	52.00	49.00	49.00
Current Liabilities	-11.1%	21.00	23.00	19.00	18.00	17.00	21.00	19.00	17.00	15.00	17.00	15.00	13.00	14.00	13.00	12.00	12.00	21.00	19.00	13.00	10.00	10.00
Long Term Debt	0.1%	36.00	36.00	36.00	36.00	36.00	35.00	34.00	35.00	35.00	35.00	35.00	40.00	40.00	39.00	39.00	39.00	31.00	35.00	39.00	39.00	39.00
LT Debt, Current	-	-	-	-	-	-	-	1.00	-	-	-	-	-	-	-	-	-	9.00	4.00	-	-	-
LT Debt, Non Current	-100.0%	-	36.00	36.00	36.00	36.00	35.00	34.00	35.00	35.00	35.00	35.00	40.00	40.00	39.00	39.00	39.00	31.00	35.00	39.00	39.00	39.00
Shareholder's Equity	-2.3%	166	169	174	177	94.00	98.00	103	111	122	134	144	154	162	169	102	108	116	63.00	69.00	78.00	83.00
Retained Earnings	-2.7%	-411	-400	-389	-379	-368	-357	-345	-331	-313	-295	-281	-265	-251	-239	-230	-220	-208	-195	-186	-175	-166
Additional Paid-In Capital	1.3%	577	569	563	557	462	455	449	443	436	430	425	419	413	408	332	328	324	258	255	252	249
Shares Outstanding	0.9%	41.00	41.00	40.00	40.00	35.00	35.00	34.00	34.00	34.00	34.00	33.00	33.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,100	-	-	-	443	-	1,000	-	-	-	-	-	394	-	-	-	391	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-229.6%	-7,571	-2,297	-2,073	-3,590	-10,753	-6,775	-6,527	-14,841	-13,512	-12,714	-9,309	-8,151	-9,359	-7,882	-5,552	-7,873	-9,355	-9,033	-7,120	-8,396	-7,078
Share Based Compensation	18.4%	7,030	5,937	5,928	5,998	6,194	5,881	5,922	5,751	5,507	4,338	4,241	4,257	4,030	3,170	3,180	2,955	2,622	1,868	1,911	1,814	1,871
Cashflow From Investing	133.6%	6,347	-18,912	-54,870	2,281	11,703	89.00	8,727	10,977	-22,608	15,378	26,753	16,571	-7,122	-67,819	-5,157	6,721	3,339	5,575	7,725	5,744	-5,553
Cashflow From Financing	-87.5%	105	842	-237	89,123	1,205	693	106	1,229	169	1,015	-5,543	2,216	601	73,038	467	-256	63,152	1,252	573	1,538	125

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SIBN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 37,867	$ 32,708
Cost of goods sold	8,002	5,924
Gross profit	29,865	26,784
Operating expenses:
Sales and marketing	29,387	27,313
Research and development	4,345	3,291
General and administrative	8,176	7,473
Total operating expenses	41,908	38,077
Loss from operations	(12,043)	(11,293)
Interest and other income (expense), net:
Interest income	2,113	932
Interest expense	(881)	(838)
Other income (expense)	(93)	74
Net loss	(10,904)	(11,125)
Other comprehensive income (loss):
Changes in foreign currency translation	29	(22)
Unrealized gain (loss) on marketable securities	(98)	90
Comprehensive loss	$ (10,973)	$ (11,057)
Net loss per share, basic (in usd per share)	$ (0.27)	$ (0.32)
Net loss per share, diluted (in usd per share)	$ (0.27)	$ (0.32)
Weighted-average number of common shares used to compute basic net loss per share (in shares)	40,934,392	34,916,106
Weighted-average number of common shares used to compute diluted net loss per share (in shares)	40,934,392	34,916,106

SIBN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,040	$ 33,271
Short-term investments	125,782	132,748
Accounts receivable, net of allowance for credit losses of $1,189 and $1,118, respectively	22,109	21,953
Inventory	21,049	20,249
Prepaid expenses and other current assets	2,647	3,173
Total current assets	203,627	211,394
Property and equipment, net	17,348	16,000
Operating lease right-of-use assets	2,415	2,706
Other non-current assets	323	325
TOTAL ASSETS	223,713	230,425
Current liabilities:
Accounts payable	7,661	4,588
Accrued liabilities and other	11,767	17,452
Operating lease liabilities, current portion	1,433	1,416
Total current liabilities	20,861	23,456
Long-term borrowings	36,107	36,065
Operating lease liabilities, net of current portion	1,192	1,511
Other long-term liabilities	16	18
TOTAL LIABILITIES	58,176	61,050
Commitments and contingencies (Note 6)
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized; 41,078,762 and 40,693,299 shares issued and outstanding, respectively	4	4
Additional paid-in capital	576,612	569,477
Accumulated other comprehensive income	266	335
Accumulated deficit	(411,345)	(400,441)
TOTAL STOCKHOLDERS’ EQUITY	165,537	169,375
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 223,713	$ 230,425

About SI-BONE Inc

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

CEO	Ms. Laura A. Francis MBA
WEBSITE	https://si-bone.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	357

SI-BONE Inc Frequently Asked Questions

What is the ticker symbol for SI-BONE Inc? What does SIBN stand for in stocks?

SIBN is the stock ticker symbol of SI-BONE Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SI-BONE Inc (SIBN)?

As of Thu May 16 2024, market cap of SI-BONE Inc is 623.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SIBN stock?

You can check SIBN's fair value in chart for subscribers.

What is the fair value of SIBN stock?

You can check SIBN's fair value in chart for subscribers. The fair value of SI-BONE Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SI-BONE Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SIBN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SI-BONE Inc a good stock to buy?

The fair value guage provides a quick view whether SIBN is over valued or under valued. Whether SI-BONE Inc is cheap or expensive depends on the assumptions which impact SI-BONE Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SIBN.

What is SI-BONE Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SIBN's PE ratio (Price to Earnings) is -14.46 and Price to Sales (PS) ratio is 4.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SIBN PE ratio will change depending on the future growth rate expectations of investors.